Recently, healthcare providers adopted telemedicine as a means to remotely grant access to patients seeking treatment for attention-deficit/hyperactivity disorder (ADHD). Two significant changes occurred during COVID-19 that facilitated the growth of telemedicine and the emergence of direct-to-consumer telemedicine-only corporations treating mental health conditions. First, the Drug Enforcement Administration issued a temporary rule suspending the requirement that providers conduct an in-person…
